New small proteins designed to target inflammation

Researchers designed miniproteins to target the IL-23 cytokine subunit p19.

Researchers designed miniprotein candidates to target the IL-23 cytokine subunit p19. These proteins aim to block the IL-23R-binding face of p19. This target drives inflammation in inflammatory bowel disease and psoriasis.

The work used a method called BindCraft to create interface-optimized hallucinations. This method produced 42 of 50 designs with an ipSAE above 0.600.60. The best design reached an ipSAE of 0.8040.804.

The ipSAE is a length-robust interface metric. It is derived from AlphaFold-initial-guess predicted aligned error. A conventional pipeline using RFdiffusion, ProteinMPNN, and ColabFold yielded no reliable predicted interface across 972 designs.

Five all-alpha-helical leads between 72-104 residues engage all six targeted hotspots. Two of these leads dock within the intact p40/p19 heterodimer. A p40-alone counter-screen returned an ipSAE of 0.000.00 for all five leads.

Current anti-p19 antibodies are large, costly, and injectable. These results require experimental validation.

Key facts

  • Five all-alpha-helical leads between 72-104 residues engage all six targeted hotspots.
  • The BindCraft method yielded 42 of 50 designs with an ipSAE above 0.600.60.
  • The designed proteins target the IL-23 cytokine subunit p19.

All sections

Edition